Drugs in ATC Class H01AC

Up to Top Level ATC Classes

Up to H - Systemic hormonal preparations, excluding sex hormones and insulins

Up to H01 - PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

Up to H01A - ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES

Drugs in ATC Class: H01AC - Somatropin and somatropin agonists

Tradename	Generic Name
GEREF	sermorelin acetate

Market Dynamics and Patent Landscape for ATC Class H01AC: Somatropin and Somatropin Agonists

Last updated: April 24, 2026

How big is the H01AC somatropin opportunity and where does growth come from?

ATC H01AC (somatropin and somatropin agonists) sits in the pediatric and adult growth hormone replacement market. Demand is driven by incidence in pediatric indications, chronic use patterns, and incremental expansion via new delivery formats and dosing regimens (weekly or reduced-frequency variants). Competitive pressure is concentrated where biologics supply is mature and where biosimilar entry creates margin compression.

Commercial shape of the class (high level)

• Core revenue pool: recombinant somatropin products across pediatric growth disorders and adult growth hormone deficiency.
• Key unit economics: therapy is chronic; pricing is shaped by tendering, reimbursement design, and biosimilar competition.
• Primary growth levers:
  • New formulations that improve adherence or reduce injection burden.
  • Biosimilar penetration in established markets.
  • Expanding clinical adoption of adjunct or combination regimens where payers accept added drug spend.

Competitive structure

• Originator portfolios: branded daily somatropin and long-acting/modified-release variants (where approved).
• Biosimilars: concentrated in geographies with regulator-approved biosimilar pathways and aggressive tendering.
• Next-generation agonists: products in the “somatropin agonist” bucket are limited in number versus daily somatropin, but they can displace share if they shift payer preferences toward reduced injection frequency.

What is the patent landscape like: concentration, expiration, and blocking positions?

The H01AC landscape is typical of biologic portfolios: layered protection across (1) the active protein (sequence and engineered variants), (2) manufacturing process and cell lines, (3) formulation and device/delivery method, (4) clinical use claims (patient selection, dosing regimens), and (5) regulatory exclusivity and pediatric extensions in the jurisdictions that use them.

Landscape density by patent “layer”

1) Molecule and variant claims

• Engineered somatropin sequences (minor amino acid changes, fusion constructs, or prolonged-action modifications).
• “Somatropin agonists” claims often cover analogs or delivery-linked constructs rather than pure sequence alternatives.

2) Manufacturing and analytical similarity

• Cell line constructs.
• Purification steps, chromatography parameters, and characterization methods.
• Stability and comparability packages that become critical during biosimilar entry.

3) Formulation, stability, and administration

• Excipients and buffering systems.
• Lyophilized versus liquid presentations.
• Viscosity, aggregation control, and storage stability.
• Injection-device integration and dosing workflows.

4) Clinical and dosing claims

• Specific dosing regimens (including titration schedules).
• Pediatric subgroup tailoring (growth velocity targets).
• Adult replacement titration.

Expiration dynamics that matter commercially

• Patent cliffs tend to be product-specific rather than class-wide, because originator portfolios protect each molecule and each formulation variant with separate claim sets.
• Biosimilar entry does not “solve” the landscape; it shifts it. New entrants face process/formulation and method-of-use barriers in jurisdictions where secondary patents survive.
• Long-acting variants raise the barrier by combining molecule engineering with formulation and delivery method claims, creating multiple independent “blocking” lines of protection.

Which products anchor ATC H01AC, and how does that drive patent strategy?

H01AC is anchored by daily recombinant somatropin and its proprietary variants, with “somatropin agonists” capturing non-identical constructs or modified-release approaches when coded under this class by regulatory authorities.

Product families that typically dominate H01AC strategy

• Daily somatropin originators and biosimilars: high supply, competitive pricing, and frequent tender-based substitution.
• Long-acting somatropin or prolonged variants: fewer competitors, higher patent density, and higher payer scrutiny on total cost versus adherence benefit.
• Somatropin agonist constructs: fewer products but often a distinct claim architecture that blocks easy “around” design.

What are the “actionable” patent blocking points for investors and R&D?

From a freedom-to-operate (FTO) and development planning perspective, H01AC blocking risk typically concentrates in four areas:

1) Formulation and stability patents that survive around active-ingredient expiry

Even when the core protein claims expire, formulation and shelf-life claims can preserve market exclusivity in practice through:

• Stability/aggregation control claims,
• Specific buffer or excipient systems,
• Presentation-specific claims (lyophilized vs ready-to-use),
• Device-adjacent claims that limit approved interchangeability.

2) Manufacturing process and cell-line IP

Biosimilars and follow-on biologics often run into:

• Process parameter claims,
• Cell line ownership and engineering claims,
• Analytical method claims used to define “similarity” or control release specifications.

3) Dosing regimen and patient-selection claims

Clinically framed claims can block marketing or require label carve-outs:

• Starting dose ranges and titration patterns,
• Pediatric dosing algorithms tied to growth velocity endpoints,
• Adult titration protocols for GH deficiency.

4) Long-acting mechanism-of-action constructs

When protection covers a prolonged-action architecture, “same sequence” workarounds are not enough because:

• Engineering changes drive both PK/PD and formulation constraints,
• Delivery method changes can implicate device and method-of-administration patents.

How do biosimilars change the dynamics in H01AC?

Biosimilars compress pricing and shift competitive leverage to:

• Manufacturing scale and cost,
• Tender and procurement relationships,
• Label parity and substitution rules,
• Device and usability differentiation.

Biosimilar impact pattern

• First-wave biosimilars often trigger price resets but do not fully remove exclusivity; residual patents still delay certain entrants or force product differentiation (device/presentation/regimen).
• Second-wave entrants gain access only after a combination of:
  • Primary protein claim expiry,
  • Residual formulation/process/method claims expiry,
  • Jurisdiction-specific litigation outcomes.

What does the “somatropin agonist” segment imply for patent risk?

Compared with standard somatropin, “somatropin agonists” generally imply:

• Fewer originators, but higher IP entanglement per product.
• Higher likelihood that the construct includes engineered features plus delivery/formulation constraints.
• Greater risk that secondary patents persist because these products often have tightly integrated PK design elements.

From an investment standpoint, that means payers may demand strong clinical and economic evidence before biosimilar-like substitution, which raises the bar for entrants even after basic expiry timelines.

Market and IP interaction: how exclusivity duration shapes launch timing

The H01AC class is shaped by a recurring schedule logic:

• Originator stabilization period: high price, low competitive pressure.
• Biosimilar “first approvals” phase: pricing pressure increases; marketing battles shift to tender access and device/presentation.
• Residual patent drag: even after principal expiry, secondary patents can create a delay window.
• Long-acting variant phase: can re-segment the market by convenience and dosing interval; the patent stack typically sustains premium pricing until late in the lifecycle.

Patent landscape summary table (structure and what to map)

The table below is a framework for how to map H01AC patents into an investment-ready view. It reflects the most common claim domains that determine whether a new entrant can launch without injunction risk.

Patent claim domain	What it covers in H01AC	Main risk it creates	Typical FTO response
Protein/construct	somatropin variants or prolonged-action constructs	Blocks “same mechanism” design-arounds	Design sequence/construct review + claim charting
Manufacturing & cell line	process parameters, engineered cell constructs	Blocks “biosimilar manufacturing” substitution	Process redesign and manufacturing patent review
Formulation & stability	excipients, buffers, aggregation and storage stability	Blocks presentation interchangeability	Reformulation FTO mapping
Device & administration	injection-device integration and use method	Blocks commercialization workflow	Device strategy and method-of-use review
Method of use	dosing regimens, titration, patient selection	Blocks label-based marketing or triggers carve-outs	Clinical program label strategy + use-claim FTO

Key takeaways

• H01AC is a mature, high-volume biologic space where biosimilar entry drives pricing, but secondary patents (formulation, process, and dosing) frequently govern actual launch timelines.
• The patent landscape typically stacks across protein/construct, manufacturing, formulation and stability, and method of use, meaning an “active-ingredient expiry” is rarely the end of exclusivity in practice.
• “Somatropin agonist” products usually have a tighter IP coupling across the construct and its delivery architecture, increasing risk for rapid entry after primary expiry.
• Investment and R&D decisions should be anchored on claim-domain mapping rather than class-level timelines because product-specific patent cliffs dominate.

FAQs

1) What are the main patent categories that delay biosimilar launches in H01AC?
Formulation and stability, manufacturing/process and cell-line claims, and dosing or method-of-use claims.

2) Why does patent risk persist even after somatropin protein patents expire?
Secondary patents tied to presentation, stability, manufacturing comparability, and clinical dosing can still support injunction or limit label entry.

3) Does the “somatropin agonist” label reduce IP risk versus standard somatropin?
No. It often increases construct-level coupling across engineered mechanism, formulation constraints, and delivery methods, which raises blocking risk.

4) What commercial factor matters most for winners in a maturing H01AC market?
Tender and reimbursement access combined with execution on device and presentation choices that avoid residual patent exposure.

5) How should investors frame timeline forecasts for H01AC entrants?
Use product-level claim charts that cover protein/construct, process, formulation/stability, device/administration, and method-of-use rather than relying on class-level expiries.

References

[1] WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index (H01AC).